NCT05366166 2026-01-28
Pembrolizumab Plus Olaparib in LA-HNSCC
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT04643379 2025-10-22
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT04825990 2022-04-07
POINT
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT02882308 2020-02-07
OPHELIA
Hellenic Cooperative Oncology Group
Phase 2 Completed